Q2 2023: Weak underlying market in the Americas and EMEA
Important events during the second quarter · Net sales decreased by 18% (21% adjusted for currency effects) to SEK 144 m (175). · The EBITDA margin amounted to 9% (26) and was burdened by items affecting comparability. Adjusted for these, the EBITDA margin was 17%. · Approval of HEAL9™ in Thailand. Enables further expansion in APAC. · Takeover of distribution of our own brand Probi® in Sweden and entry into Norway with new agreements with pharmacies. · Exclusive distributor of BLIS K12™ and BLIS M18™ ingredients in the US and Canada as of August 1. · New partnership with